Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Arun Azad, PhD
Advertisement
Articles by Arun Azad, PhD
Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.
Advertisement
Latest Updated Articles
Dr. Azad on the Design of the ARCHES Trial in mHSPCPublished: October 20th 2020 | Updated:
Dr. Azad on the Significance of the PROfound Trial in mCRPCPublished: October 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5